Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 30.00
+8.40 (38.89%)
Last updated: Jun 3, 2026, 7:55 PM CET
Legend Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -236.5 | -282.6 | -158.1 | -520.2 | -445.72 | -407.2 |
Depreciation & Amortization | 39.51 | 28.9 | 21.4 | 18.5 | 18.39 | 13.92 |
Stock-Based Compensation | 68 | 64.6 | 68.9 | 47.7 | 34.34 | 20.16 |
Other Adjustments | 147.25 | 200.4 | -93 | 133.1 | 0.8 | 12.19 |
Change in Receivables | -0.2 | -5.7 | 93.8 | -99 | 50.32 | 24.59 |
Changes in Inventories | -0.6 | -4.5 | -17.2 | -12.7 | -13.89 | 0.05 |
Changes in Accounts Payable | 16.8 | 44.4 | 14.1 | -50.2 | 72.45 | 1.81 |
Changes in Accrued Expenses | 10 | 36.1 | 43.9 | -2.7 | 119.29 | 140.75 |
Changes in Income Taxes Payable | -6.7 | -18.4 | -1.6 | 0.3 | 3.71 | 0.56 |
Changes in Unearned Revenue | -36.1 | -40 | -49.7 | 100 | - | - |
Changes in Other Operating Activities | -81.27 | -123.4 | -66.5 | -8.1 | -40.95 | -5.28 |
Operating Cash Flow | -81.7 | -100.2 | -144 | -393.3 | -201.28 | -198.47 |
Capital Expenditures | -34.1 | -28.6 | -14.1 | -20.1 | -20.93 | -42.2 |
Sale of Property, Plant & Equipment | - | - | - | - | - | 0 |
Purchases of Intangible Assets | -41.8 | -38.8 | -54.9 | -101.4 | -16.16 | -4.92 |
Purchases of Investments | -4,765 | -4,543 | -2,712 | -4,863 | -654.97 | -377.96 |
Proceeds from Sale of Investments | 5,131 | 5,320 | 1,928 | 5,069 | 613.71 | 230.08 |
Other Investing Activities | - | - | 2.5 | 8.9 | 1.25 | - |
Investing Cash Flow | 285 | 709.6 | -850.6 | 92.9 | -77.09 | -194.98 |
Issuance of Common Stock | 1.96 | 3.3 | 9.7 | 795.2 | 380.57 | 628.08 |
Net Common Stock Issued (Repurchased) | 1.96 | 3.3 | 9.7 | 795.2 | 380.57 | 628.08 |
Other Financing Activities | -4.1 | -3.6 | -4 | -3.8 | -2.6 | -1.42 |
Financing Cash Flow | -2.17 | -0.3 | 5.7 | 791.4 | 377.98 | 626.66 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 3.5 | 6.1 | -2.1 | 0.7 | -2.51 | 0.03 |
Net Cash Flow | 204.7 | 615.2 | -991 | 491.7 | 99.6 | 233.22 |
Free Cash Flow | -115.8 | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 |
FCF Margin | -10.17% | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% |
Free Cash Flow Per Share | -0.63 | -0.70 | -0.86 | -2.35 | -1.40 | -1.71 |
Levered Free Cash Flow | -342.72 | -402.3 | -246.7 | -493.3 | -308.29 | -293.98 |
Unlevered Free Cash Flow | -211.89 | -248.86 | -416.2 | -501.17 | -297.48 | -293.09 |